Companies Cryptocurrencies
Akero Therapeutics Inc
Akero Therapeutics Inc
Exchange: NasdaqGS
IPO Date: 20/06/2019
CEO: Dr. Andrew Cheng
Biotechnology Healthcare 🔗
  • AKRO
  • 20.75
  • 723384448
    market cap
  • -0.70000076
If you bought

shares of Akero Therapeutics Inc (AKRO) on
You would have made
Old Price $12 Current Price $12

Akero Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in South San Francisco, California and currently employs 10 full-time employees. The firm is engaged in nonalcoholic steatohepatitis (NASH), a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease, or NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. The Company’s lead product candidate, AKR-001, which the Company is developing as a treatment for patients with NASH, is an analog of fibroblast growth factor 21 (FGF21). FGF21 is an endogenously-expressed hormone that regulates metabolism of lipids, carbohydrates and proteins throughout the body.

Address: 170 Harbor Way South San Francisco CALIFORNIA 94080

Stay updated.